A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis

Naour, François Le; Brichory, Franck; Misek, David E.; Bréchot, Christian; Hanash, Samir M.; Beretta, Laura

doi:10.1074/mcp.m100029-mcp200

Cited by 156 publications

(92 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical material was used for proteome analysis comparing normal liver tissue and HCC, [15][16][17] or normal liver, cirrhotic liver, and HCC 18 or sera from HCC patients for the identification of tumor autoantibodies. 19 Different protein variants were proposed as tumor-marker candidates. An integrated proteome database for the study of human HCC has been constructed.…”

mentioning

confidence: 99%

Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas

et al. 2004

View full text Add to dashboard Cite

The proteomic approach is a valuable tool to detect and identify proteins that are associated with cancer. In previous investigations on experimentally induced rat hepatomas, we detected aldose reductase-like protein (ARLP) as a highly significant marker protein. Our present study was intended to look for the presence of similar tumor-associated marker proteins on human hepatocellular carcinomas (HCC). We found several novel tumorassociated protein variants that represent members of the aldo-keto reductase (AKR) superfamily. Human aldose reductase-like protein-1 (hARLP-1) was the most prominent tumorassociated AKR member detected in HCC by 2-dimensional electrophoresis (2-DE) and identified by mass spectrometric fingerprinting. The enzyme was found in 4 distinct forms H uman hepatocellular carcinoma (HCC) ranks fifth in worldwide cancer incidence and is an important component of public health. Many HCC risk factors are known, including hepatitis B or C (HBV or HCV) infection, ingestion of aflatoxin-contaminated food, and alcohol. 1,2 The development of HCC is associated with multiple changes at the messenger RNA (mRNA) and/or protein level, some of them serving as tumor markers, e.g., ␣-fetoprotein, 3 or, less specifically, cyclin D1 or the proliferating cell nuclear antigen. 4 Misprogramming of genetic information in cancer is reflected by quantitative and/or qualitative protein alterations. These protein alterations might represent tumor markers that are useful in the diagnosis of human tumors and may also help the understanding of mechanisms of tumor induction and development. Proteome analysis of liver proteins and HCC were predominantly performed using either chemically induced hepatomas in animals (predominantly the rat 5-10 ) or human HCC cell lines, such as HepG2 and Huh7 cells, 11 BEL-7404 cells, 12 or HCC-M cells. 2,13,14 Numerous so-called tumor-associated or cancer-related proteins were identified; these provide valuable information for the establishment of HCC protein databases. 2,[11][12][13][14] Comparative analysis of liver tissue and hepatocellular carcinomas might give additional insights into the induction or repression of tumor-associ-

show abstract

mentioning

confidence: 99%

Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Cette approche, qui a été nommée par la suite SERPA (serological proteome analysis) [18], Proteomex [19,20] ou SPEAR (serological and proteomic evaluation of antibody response) [21], a été utilisée avec succès pour identifier des AAT dans plusieurs autres types de cancers. Sans vouloir être exhaustif, on peut citer, par exemple, la protéine peroxirédoxine 6 dans le carcinome squameux de l'oesophage [22,23], les protéines triosephosphate isomérase (Tim) et superoxyde dismutase (MnSOD) dans le carcinome squameux du poumon [22,23], la calréticuline dans les cancers hépatique [24] et du pancréas [25] et RS/DJ1 dans le cancer du sein [26].…”

Section: Analyse Sérologique à Partir Des Techniques De Protéomique Cunclassified

Étude de la réaction immunitaire humorale aux cancers par des approches protéomiques

2008

View full text Add to dashboard Cite

“…In principle, human proteome arrays could be used in this way to identify new autoantigens, which may help to guide the development of more efficacious antigen-specific toleration therapies [50]. Similarly, recent reports of autoantibodies against a number of antigens in sera from patients with different types of cancer suggest that protein microarrays with large numbers of tumorexpressed proteins could facilitate the identification of markers for cancer screening [51][52][53][54]. In some cases, as with HER-2/neu, the cancer biomarkers may even become therapeutic targets [55].…”

Section: Immune Profilingmentioning

confidence: 99%

Microarrays to characterize protein interactions on a whole‐proteome scale

Schweitzer¹,

Predki²,

Snyder

2003

Proteomics

149

View full text Add to dashboard Cite

Protein microarrays contain a defined set of proteins spotted and analyzed at high density, and can be generally classified into two categories; protein profiling arrays and functional protein arrays. Functional protein arrays can be made up of any type of protein, and therefore have a diverse set of useful applications. Advantages of these arrays include low reagent consumption, rapid interpretation of results, and the ability to easily control experimental conditions. The ultimate form of a functional protein array consists of all of the proteins encoded by the genome of an organism; such an array would be the whole proteome equivalent of the whole genome DNA arrays that are now available. While proteome microarrays may not have reached the stage of maturity of DNA microarrays, recent developments have shown that many of the barriers holding back the technology can be overcome. Arrays of this type have already been used to rapidly screen large numbers of proteins simultaneously for biochemical activities, protein-protein interactions, protein-lipid interactions, protein-nucleic acid interactions, and protein-small molecule interactions. Eventually, functional protein arrays will be used to facilitate various steps in the drug discovery and early development processes that are currently bottlenecks in the drug development continuum.

show abstract

A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis

Cited by 156 publications

References 36 publications

Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas

Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas

Étude de la réaction immunitaire humorale aux cancers par des approches protéomiques

Microarrays to characterize protein interactions on a whole‐proteome scale

Contact Info

Product

Resources

About